NO20072058L - Inhibitorer av interaksjonen mellom MDM2 og P53 - Google Patents

Inhibitorer av interaksjonen mellom MDM2 og P53

Info

Publication number
NO20072058L
NO20072058L NO20072058A NO20072058A NO20072058L NO 20072058 L NO20072058 L NO 20072058L NO 20072058 A NO20072058 A NO 20072058A NO 20072058 A NO20072058 A NO 20072058A NO 20072058 L NO20072058 L NO 20072058L
Authority
NO
Norway
Prior art keywords
mdm2
interaction
inhibitors
fior
flour
Prior art date
Application number
NO20072058A
Other languages
English (en)
Other versions
NO341281B1 (no
Inventor
Janine Arts
Jean Fernand Armand Lacrampe
Christophe Meyer
Yannick Aime Eddy Ligny
Imre Christian Francis Csoka
Hijfte Luc Van
Bruno Schoentjes
Camille Georges Wermuth
Bruno Giethlen
Jean-Marie Contreras
Muriel Joubert
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928531&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072058(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20072058L publication Critical patent/NO20072058L/no
Publication of NO341281B1 publication Critical patent/NO341281B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Foreliggende oppfinnelse tilveiebringer fiorbindelser med fiormel (I), deres anvendelse som en inhibitor av en p53-MDM2-interaksjon samt fiarmasøytisk sammensetninger omfiattende fiorbindelsene med fiormel (I) hvori n, m, p, s, t, R\ R^ R^ R'*, R^ R^ R^ X, Y, Q og Z har definerte betyninger.
NO20072058A 2004-09-22 2007-04-23 Inhibitorer av interaksjonen mellom MDM2 og P53 NO341281B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04077630 2004-09-22
US61390204P 2004-09-28 2004-09-28
PCT/EP2005/054604 WO2006032631A1 (en) 2004-09-22 2005-09-16 Inhibitors of the interaction between mdm2 and p53

Publications (2)

Publication Number Publication Date
NO20072058L true NO20072058L (no) 2007-04-23
NO341281B1 NO341281B1 (no) 2017-10-02

Family

ID=34928531

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072058A NO341281B1 (no) 2004-09-22 2007-04-23 Inhibitorer av interaksjonen mellom MDM2 og P53

Country Status (30)

Country Link
US (2) US7834016B2 (no)
EP (1) EP1809622B1 (no)
JP (1) JP5156378B2 (no)
KR (1) KR101331786B1 (no)
CN (1) CN101023074B (no)
AP (1) AP2446A (no)
AR (1) AR053412A1 (no)
AT (1) ATE474833T1 (no)
AU (1) AU2005286525B2 (no)
BR (1) BRPI0515594B8 (no)
CA (1) CA2579915C (no)
CR (1) CR9081A (no)
DE (1) DE602005022472D1 (no)
DK (1) DK1809622T3 (no)
EA (1) EA012452B1 (no)
EC (1) ECSP077335A (no)
ES (1) ES2349358T3 (no)
HK (1) HK1107651A1 (no)
HR (1) HRP20100561T1 (no)
IL (1) IL182009A (no)
MX (1) MX2007003375A (no)
MY (1) MY136800A (no)
NO (1) NO341281B1 (no)
NZ (1) NZ553646A (no)
SG (1) SG155941A1 (no)
SI (1) SI1809622T1 (no)
TW (1) TWI372758B (no)
UA (1) UA91027C2 (no)
WO (1) WO2006032631A1 (no)
ZA (1) ZA200702341B (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
EP1881983B1 (en) * 2005-05-20 2012-01-11 Vertex Pharmaceuticals, Inc. Pyrrolopyridines useful as inhibitors of protein kinase
JP5162574B2 (ja) * 2006-03-22 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｄｍ２及びｐ５３間の相互作用のインヒビターとしての環式アルキルアミン誘導体
JP5385125B2 (ja) * 2006-03-22 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
MX2008013238A (es) * 2006-04-12 2008-10-21 Merck & Co Inc Antagonistas de los canales de calcio de tipo t de piridil amida.
WO2008006051A2 (en) 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
WO2008121442A2 (en) * 2007-02-09 2008-10-09 The Uab Research Foundation Pa28-gamma regulation in cells
US20100129933A1 (en) * 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
US8853406B2 (en) 2007-08-06 2014-10-07 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53
CA2699707C (en) * 2007-09-21 2016-05-17 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US8637513B2 (en) 2007-10-24 2014-01-28 Merck Sharp & Dohme Corp. Heterocycle phenyl amide T-type calcium channel antagonists
US8268777B2 (en) * 2007-12-05 2012-09-18 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
CA2708047A1 (en) * 2007-12-06 2009-06-11 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis c protease inhibitors
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US8541442B2 (en) 2009-02-04 2013-09-24 Janssen Pharmaceutica N.V. Indole derivatives as anticancer agents
US20120135089A1 (en) * 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
NZ600430A (en) 2009-11-12 2014-06-27 Univ Michigan Spiro-oxindole mdm2 antagonists
CN102892768A (zh) 2009-12-30 2013-01-23 艾科尔公司 被取代的吡咯并氨基嘧啶化合物
CA2802290A1 (en) * 2010-07-02 2011-12-05 Sygenta Participations Ag Novel microbiocidal dioxime ether derivatives
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
EA201390682A1 (ru) 2010-11-12 2014-01-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Спирооксиндольные антагонисты mdm2
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
UY34591A (es) * 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2509808C1 (ru) * 2012-10-30 2014-03-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) СПОСОБ ОПРЕДЕЛЕНИЯ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКИХ К ДЕЙСТВИЮ ПРЕПАРАТОВ, РЕАКТИВИРУЮЩИХ БЕЛОК р53
KR20140059002A (ko) * 2012-11-07 2014-05-15 한국과학기술원 다제내성 종양 치료를 위한 항암제 및 치료방법
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
HUE042335T2 (hu) 2014-10-14 2019-06-28 Vitae Pharmaceuticals Inc ROR-gamma dihidropirrolopiridin inhibitorai
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
JP6564449B2 (ja) 2015-02-20 2019-08-21 第一三共株式会社 がんの併用治療法
MX2017014287A (es) * 2015-05-11 2018-03-07 Basf Se Proceso para preparar 4-amino-piridazinas.
BR122019027518B8 (pt) * 2015-05-11 2021-04-13 Basf Se processos para a preparação de um composto, composto de amina de dicloropiridazina e mistura do composto de amina de dicloropiridazina
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
AU2016301188A1 (en) 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US11192898B2 (en) 2016-04-06 2021-12-07 The Regents Of The University Of Michigan MDM2 protein degraders
CA3020281A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
MX2020000887A (es) 2017-07-24 2020-07-22 Vitae Pharmaceuticals Llc Inhibidores de ror?.
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
CN108409839B (zh) * 2018-02-13 2020-08-11 中国人民解放军军事科学院军事医学研究院 一种MDM2与p53相互作用的多肽抑制剂及其应用
WO2019164794A1 (en) * 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
AU2021215709A1 (en) 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
TR202002325A2 (tr) * 2020-02-17 2021-08-23 Bahcesehir Ueniversitesi Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-4
CN113293046B (zh) * 2021-05-26 2021-11-30 安徽博洋润滑科技有限公司 一种低发尘润滑脂及其制备方法
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9201755D0 (en) 1992-01-28 1992-03-11 British Bio Technology Compounds
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
JP2003524620A (ja) * 1999-03-24 2003-08-19 アノーメッド インコーポレイティド ケモカインレセプター結合複素環化合物
WO2001042224A1 (en) * 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
JP2004508421A (ja) 2000-09-15 2004-03-18 アノーメッド　インコーポレイティド ケモカインレセプター結合性ヘテロ環式化合物
AU2002303094B2 (en) 2001-03-29 2006-11-23 Eli Lilly And Company N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
WO2003040402A2 (en) * 2001-11-09 2003-05-15 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
JP4497921B2 (ja) 2001-11-13 2010-07-07 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換１，４−ベンゾジアゼピンおよび癌の処置のためのその使用
JP4477351B2 (ja) 2001-12-18 2010-06-09 エフ．ホフマン−ラ ロシュ アーゲー シス−２，４，５−トリフェニル−イミダゾリン類及び腫瘍の処理へのそれらの使用
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
GB0428187D0 (en) 2004-12-23 2005-01-26 Univ Liverpool Cancer treatment
AU2006205850A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
EP2314297A1 (en) 2006-04-05 2011-04-27 Novartis AG Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer

Also Published As

Publication number Publication date
AP2007003947A0 (en) 2007-04-30
NO341281B1 (no) 2017-10-02
AU2005286525A1 (en) 2006-03-30
BRPI0515594A (pt) 2008-07-29
CR9081A (es) 2008-11-24
JP5156378B2 (ja) 2013-03-06
EP1809622B1 (en) 2010-07-21
NZ553646A (en) 2010-07-30
TW200626579A (en) 2006-08-01
IL182009A0 (en) 2007-07-24
CN101023074B (zh) 2012-10-10
CA2579915C (en) 2010-06-22
HK1107651A1 (en) 2008-04-11
EA200700699A1 (ru) 2007-08-31
US8404683B2 (en) 2013-03-26
SI1809622T1 (sl) 2010-11-30
MX2007003375A (es) 2007-05-07
ATE474833T1 (de) 2010-08-15
US7834016B2 (en) 2010-11-16
EP1809622A1 (en) 2007-07-25
ECSP077335A (es) 2007-04-26
HRP20100561T1 (hr) 2010-11-30
WO2006032631A1 (en) 2006-03-30
KR101331786B1 (ko) 2013-11-21
JP2008513532A (ja) 2008-05-01
ZA200702341B (en) 2010-09-29
AU2005286525B2 (en) 2011-06-16
KR20070058622A (ko) 2007-06-08
DK1809622T3 (da) 2010-11-08
UA91027C2 (ru) 2010-06-25
ES2349358T3 (es) 2010-12-30
AR053412A1 (es) 2007-05-09
BRPI0515594B8 (pt) 2021-05-25
US20080039472A1 (en) 2008-02-14
US20110053937A1 (en) 2011-03-03
TWI372758B (en) 2012-09-21
BRPI0515594B1 (pt) 2020-09-24
CA2579915A1 (en) 2006-03-30
SG155941A1 (en) 2009-10-29
AP2446A (en) 2012-08-31
IL182009A (en) 2012-06-28
DE602005022472D1 (de) 2010-09-02
MY136800A (en) 2008-11-28
EA012452B1 (ru) 2009-10-30
CN101023074A (zh) 2007-08-22

Similar Documents

Publication Publication Date Title
NO20072058L (no) Inhibitorer av interaksjonen mellom MDM2 og P53
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
NO20062892L (no) 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
ATE547415T1 (de) Inhibitoren der wechselwirkung zwischen mdm2 und p53
NO20063129L (no) Substituerte 6-cykloheksylalkylsubstituerte 2-kinolinoner og 2-kinoksalinoner som poly(ADP-ribose) polymeraseinhibitorer
WO2004074244A3 (en) Pyrimidine compounds
SE0302811D0 (sv) Novel compounds
IL180722A0 (en) Thienopyrimidine derivatives and pharmaceutical compositions containing the same
CY1109006T1 (el) Παραγωγα πουρινης ως αναστολεις κινασης
NO20063028L (no) 6-substituerte 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
TNSN08191A1 (en) Kinase inhibitors
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
ATE470665T1 (de) Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
MX2010003060A (es) Inhibidores de la interaccion entre mdm2 y p53.
MX2008001538A (es) Aril piridinas y metodos para su uso.
UA85505C2 (en) Kinase inhibitors
WO2007068728A3 (en) N-substituted pyrrolopyridinones active as kinase inhibitors
TW200624429A (en) Novel cysteine protease inhibitors
GB0308201D0 (en) Novel compounds
WO2006078887A3 (en) Methylphenidate derivatives and uses of them
BRPI0417205A (pt) composições farmacêuticas

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees